Daniel receives funding from Familien Blix Fond
We're thrilled to announce that Daniel has received funding from Familien Blix Fond on the project "Quinolinate Phosphoribosyltransferase (QPRT) as a target gene for the reduction of resistance development in ER-positive breast cancer." This project will allow us to validate computational predictions on a gene that is potentially involved in resistance to tamoxifen, which Daniel recently found through in silico knock-down experiments in breast cancer. We will be collaborating with Xavier Tekpli and Salim Ghannoum from Oslo University Hospital. NCMM put together a news article about the project that can be accessed here.